A Functional Genetic Score in the ZMIZ1/TGF-β/STAT Pathway Predicts Early Biologic Discontinuation in Psoriasis Patients Treated with Anti-TNF and Anti-IL12/23 Agents
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03350-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Juan de Luque und 13 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, 14004, Córdoba, Spain. Hauptthemen laut MEDLINE: Psoriasis, Transcription Factors. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
INTRODUCTION: Biologic drug survival in psoriasis is variable. While clinical factors such as obesity and comorbidities contribute to early discontinuation, genetic predictors are less defined. The ZMIZ1/TGF-β/STAT axis regulates immune-metabolic responses and represents a promising pharmacogenetic target. METHODS: We retrospectively analyzed 875 biologic treatment courses from 312 patients with moderate-to-severe psoriasis (NCT07041112). A pathway-based genetic score was derived from seven single nucleotide polymorphisms (SNPs) in the ZMIZ1/TGF-β/STAT axis and dichotomized at the median. The primary outcome was time to biologic discontinuation, assessed with Kaplan-Meier curves and Cox proportional hazards models adjusted for demographic, clinical, and inflammatory covariates. RESULTS: Patients with a high genetic score had significantly longer drug survival (hazard ratio [HR] = 0.74; 95% confidence interval [CI]: 0.62-0.89; p = 0.0015), despite elevated baseline tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-15, and leptin. This indicates that genetic background simultaneously conditioned immune-metabolic activation and treatment persistence. Predictive value was strongest for anti-IL12/23 agents (HR = 0.44; 95% CI: 0.26-0.75; p = 0.002) and anti-TNF therapies (HR = 0.79; 95% CI: 0.62-0.99; p = 0.045), but absent for anti-IL17/IL-23 agents after adjustment. None of the circulating biomarkers independently predicted survival. CONCLUSION: A functional genetic score in the ZMIZ1/TGF-β/STAT pathway independently predicted long-term biologic persistence in psoriasis, particularly with anti-TNF and anti-IL12/23 therapies. Its association with immune-metabolic activation suggests that genetic background shapes both inflammatory status and treatment durability. Incorporating such profiling into predictive algorithms may improve treatment personalization and biologic retention. TRIAL REGISTRATION: Trial Registration NCT07041112. Psoriasis is a chronic skin disease that can be treated with biologic drugs targeting specific immune pathways. These treatments are highly effective, but many patients stop them earlier than expected due to reduced benefit or side effects. Predicting long-term response is a key challenge for doctors. In this study, we examined whether genetic differences could explain how long patients remain on biologic therapy. We focused on genes in the ZMIZ1 (zinc finger MIZ-type containing 1), TGF-β (transforming growth factor beta), and STAT (signal transducer and activator of transcription) pathways, which regulate immune and metabolic responses. A genetic score was created using seven common variants and tested in over 800 treatment courses from more than 300 patients with moderate-to-severe psoriasis. Patients with higher scores had longer treatment persistence, even though they showed higher baseline inflammation, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-15, and leptin. The strongest associations were found for anti-TNF and anti-IL12/23 therapies, while no predictive value was observed for anti-IL17 or anti-IL23 agents. These results suggest that genetic background influences both baseline immune activity and drug survival. Incorporating such genetic scores into routine care could support more personalized treatment and improve long-term outcomes for people with psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, 14004, Córdoba, Spain.
- Department of Dermatology, Reina Sofía University Hospital, 14004, Córdoba, Spain.
- Laboratory for Investigative Dermatology, Center for Clinical Translational Science, The Rockefeller University, New York, NY, 10065, USA.
- Department of Pharmacy, Reina Sofía University Hospital, 14004, Córdoba, Spain.
- Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, 14004, Córdoba, Spain. teresa.lopezvinau.sspa@juntadeandalucia.es.
- Department of Pharmacy, Reina Sofía University Hospital, 14004, Córdoba, Spain. teresa.lopezvinau.sspa@juntadeandalucia.es.
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
de Luque, J., Mochón-Jiménez, C., Rivera-Ruiz, I., Gay-Mimbrera, J., Fuentes-Duculan, J., Coats, I., Aguilar-Luque, M., Isla-Tejera, B., Nieto, A. V., Galán-Gutiérrez, M., López, T. L., Suarez-Fariñas, M., Krueger, J. G., & Ruano, J. (2025). A Functional Genetic Score in the ZMIZ1/TGF-β/STAT Pathway Predicts Early Biologic Discontinuation in Psoriasis Patients Treated with Anti-TNF and Anti-IL12/23 Agents. Advances in Therapy. https://doi.org/10.1007/s12325-025-03350-0
Vancouver
de Luque J, Mochón-Jiménez C, Rivera-Ruiz I, Gay-Mimbrera J, Fuentes-Duculan J, Coats I, et al. A Functional Genetic Score in the ZMIZ1/TGF-β/STAT Pathway Predicts Early Biologic Discontinuation in Psoriasis Patients Treated with Anti-TNF and Anti-IL12/23 Agents. Advances in Therapy. 2025. doi:10.1007/s12325-025-03350-0
BibTeX
@article{deLuque2025,
author = {de Luque, Juan and Mochón-Jiménez, Carmen and Rivera-Ruiz, Irene and Gay-Mimbrera, Jesús and Fuentes-Duculan, Judilyn and Coats, Israel and Aguilar-Luque, Macarena and Isla-Tejera, Beatriz and Nieto, Antonio Vélez-García and Galán-Gutiérrez, Manuel and López, Teresa López-Viñau and Suarez-Fariñas, Mayte and Krueger, James G and Ruano, Juan},
title = {A Functional Genetic Score in the ZMIZ1/TGF-β/STAT Pathway Predicts Early Biologic Discontinuation in Psoriasis Patients Treated with Anti-TNF and Anti-IL12/23 Agents},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03350-0}
}
EUVIMED